Sánchez-Piedra, Carlos
Sueiro-Delgado, Diana
García-González, Javier
Ros-Vilamajo, Inmaculada
Prior-Español, Agueda
Moreno-Ramos, Manuel José
Garcia-Magallon, Blanca
Calvo-Gutiérrez, Jerusalen
Perez-Vera, Yanira
Martín-Domenech, Raquel
Ruiz-Montesino, Dolores
Vela-Casasempere, Paloma
Expósito, Lorena
Sánchez-Alonso, Fernando
González-Davila, Enrique
Díaz-González, Federico
Article History
Received: 25 March 2021
Accepted: 12 July 2021
First Online: 23 July 2021
Competing interests
: Dra Diana Sueiro-Delgado reports other from GSK, other from PFIZER, other from NOVARTIS, other from ABBVIE, outside the submitted work. Dra. Blanca Garcia-Magallon reports personal fees from MSD, non-financial support from MSD, personal fees from Celgene, personal fees from Amgen, personal fees from Pfizer, outside the submitted work. Dra. Yanira Perez-Vera reports non-financial support from ROCHE, non-financial support from ABBVIE, non-financial support from MSD, non-financial support from UCB PHARMA, outside the submitted work. Other authors have no conflict of interest.